



Title	Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer
Author(s)	Takeuchi, Shintaro; Baghdadi, Muhammad; Tsuchikawa, Takahiro et al.
Description	Supplementary data for this article are available at Cancer Research Online http://cancerres.aacrjournals.org/content/75/13/2629.figures-only
Citation	Cancer research, 75(13), 2629-2640 https://doi.org/10.1158/0008-5472.CAN-14-2921
Issue Date	2015-07-01
Doc URL	https://hdl.handle.net/2115/62325
Type	journal article
File Information	supplementary_tables+figures.pdf, Supplementary Tables and Figures



Supplementary Table

A. Association between GM-CSF and clinicopathological variables

Variable	GM-CSF low (n=20)	GM-CSF high (n=48)	<i>P</i> value ^a
Age			0.048
≤ 66 years	14	21	
> 66 years	6	27	
Sex			0.252
Male	15	29	
Female	5	19	
Tumor location			0.15
Pancreas head	13	39	
Pancreas body, tail	7	9	
Tumor size			0.659
≤ 3 cm	8	22	
> 3 cm	12	26	
Lymph node metastasis			0.667
positive	14	31	
negative	6	17	
Lymphatic invasion			0.539
positive	16	35	
negative	4	13	
Venous invasion			0.712
positive	17	39	
negative	3	9	
UICC stage			0.455
I+II	6	19	
III	14	29	

NOTE. GM-CSF expression was correlated with age, whereas there were no statistically significant differences in terms of other variables. ^a Estimated by χ^2 test

B. Clinicopathological features of enrolled PDAC patients with or without chemotherapy

	Pre-operative chemotherapy (-) (n=9)	Pre-operative chemotherapy (+) (n=6)	P-value ^a
Age(years)	69 (51-85)	61 (43-68)	0.301
Sex(male/female)	3/6	2/4	1.000
Pathological UICC stage I +II/ III	8/1	3/3	0.235

NOTE. There were no statistically significant differences in terms of the background characteristics between patients with or without pre-operative chemotherapy.

^a Estimated by Fisher's exact test

C. Clinicopathological features including drug regimen or chemotherapeutic response of enrolled 6 PDAC patients with pre-operative chemotherapy

Age	Sex	Regimen	Clinical response ^a	Pathological response ^b
43	Female	GEM+S-1	PR	II a
65	Male	GEM	PR	II a
55	Male	GEM+S-1	PR	I
66	Female	GEM+S-1	SD	I
68	Female	GEM+5FU	PR	II b
67	Female	GEM+5FU	PR	II a

NOTE. GEM: Gemcitabine, S-1: tegafur, gimeracil, oteracil, potassium, 5-FU: 5-fluorouracil. PR: Partial response, SD: Stable disease.


^a Estimated according to RECIST criteria version 1.1.(1)

^b Estimated according to Evans's score: tumor destruction up to 10%, grade I; 10–50%, grade II a ; 50–90%, grade II b; >90%, grade III ; and complete response, grade IV. (2)


Supplementary References

1. Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A.T., Christian, M.C., et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216.
2. Evans, D.B., Rich, T.A., Byrd, D.R., Cleary, K.R., Connelly, J.H., Levin, B., Charnsangavej, C., Fenoglio, C.J., and Ames, F.C. 1992. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. *Arch Surg* 127:1335-1339.



Supplementary figure.1




Supplementary figure.2




Supplementary figure.3



Supplementary figure.4



Supplementary figure.5



SF: surgery first; N=10
AS: adjuvant surgery; N=7